Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey
This prospective phase IV study aimed to evaluate the efficacy and safety. Response and remission rates were 70% and 40% (week 6) and 67% and 36%, respectively.
